演題詳細

ポスター / Poster

ポスター 20 (Poster 20) :Mantle Cell Lymphoma

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
三浦 勝浩 (Katsuhiro Miura):1
1:日本大学 血液膠原病内科
 
前へ戻る

Multicentric prospective clinical study of R-CMD therapy for indolent B-cell lymphoma and MCL

演題番号 : PS-1-146

坂井 知之 (Tomoyuki Sakai):1、正木 康史 (Yasufumi Masaki):1、大槻 希美 (Nozomi Ootsuki):2、岸 慎治 (Shinji Kishi):3、宮園 卓宜 (Takayoshi Miyazono):4、浦崎 芳正 (Yoshimasa Urasaki):3、村上 純 (Jun Murakami):4、佐藤 智美 (Tomomi Sato):1、中村 拓路 (Takuji Nakamura):1、岩男 悠 (Haruka Iwao):1、中島 章夫 (Akio Nakajima):1、三木 美由貴 (Miyuki Miki):1、藤田 義正 (Yoshimasa Fujita):1、田中 真生 (Masao Tanaka):1、福島 俊洋 (Toshihiro Fukushima):1、岡崎 俊朗 (Toshiro Okazaki):1、梅原 久範 (Hisanori Umehara):1

1:Department of Hematology & Immunology Kanazawa Medical University, Japan、2:Internal Medicine, National Hospital Organization Awara National Hospital, Japan、3:Department of Hematology and Oncology, University of Fukui Hospital, Japan、4:Department of Gastroenterology and Hematology, University of Toyama, Japan

 

Purpose:Little consensusu of first line therapy in low grade B-cell non-Hodgkin lymphomas(LGNHL) and mantle cell lymphoma(MCL) patients is established. A purine analogue, cladribine is effecive to resting lymphocytes and may lead to better thrapy response to indolent lymphoma. We analyzed the efficacy and safety of combination chemotherapy that consist of rituximab, cladribine, mitoxantrone and dexamethasone for patients with LGNHL and MCL. Patients and Methods: From January 2008 to August 2011, 33 patients, including 21 FL, 3 MCL, 5 MZB, 1 HCL, 1 WM,1 indolent B cell lymphoma and 1 LPL were treated. Median age is 65 years old. Patients were treated by combination chemotherapy, R-CMD that consist of 375mg/m 2 of rituximab intravenously on day 1 and 0.10mg/kg of cladribine intravenously on day 1 to 3 and 8mg/m2 of mitoxantrone intravenously on day 1 and 8mg/body of dexamethasone intravenously on day 1 to 3 evry 21 days of total 4 cycles followed by 4 cycles of 375mg/m 2 of rituximab intravenously. Results: 26 of 33 patients achieved CR. 6 patients PR (4 FL, 1 MZB, 1 WM), 1 patient PD(FL). 3 patients(1 FL, 2 MCL) relapsed. Grade 3 or 4 neutropeia, lymphopenia and thrombocytopenia were observed in 72%, 76% and 8.3% of patients, respectively, but these were recoverd with short duration. Non-hematological toxicities were very mild, although grade 2 constipation was observed in almost patients. Alopecia was infrequent. Conclusion: R-CMD therapy was effective and hopeful first line chemotherapy for LGNHL and MCL with tolerable adverse effect. Further long-term follow-up is needed.

前へ戻る